Celldex Therapeutics, Inc. (CLDX) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -16748.0%, revenue growth -97.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $1.54M |
| Revenue (TTM) | $0.0B |
| Net Margin | -16748.0% |
| Return on Equity | -42.1% |
| Operating Margin (TTM) | -207534.4% |
| Current Ratio | 11.82 |
| Interest Coverage | -87.9 |
| Revenue Growth (YoY) | -97.0% |
| EPS Growth (YoY) | 10.6% |
| FCF Growth (YoY) | 35.4% |
| Price / Book | 4.05 |
| Price / Sales | 18451.94 |
| FCF Yield | -8.4% |
| Altman Z-Score | 21.41 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
CLDX overview · CLDX earnings · CLDX KPIs · CLDX documents · CLDX ownership · CLDX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.